Linoleic acid
|
Basic information |
| Metabolite name | Linoleic acid |
 | HMDB0000673 |
 |
C01595 |
 |
5280450 |
| Synonyms | 9,12-Octadecadienoic acid; |
| No. of studies | 33 |
|
Basic information |
| Metabolite name | Linoleic acid |
| HMDB0000673 |
|
C01595 |
|
5280450 |
| Synonyms | 9,12-Octadecadienoic acid; |
| No. of studies | 33 |
|
Relationship between Linoleic acid and depression (count: 33) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M001 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M001 | Type4 | remitted group vs. non-remitted group | Plasma | Human | Up |
| Study M005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M020 | Type1 | CUMS group vs. control group | Heart | Sprague-Dawley rat | Down |
| Study M028 | Type2 | placebo group 4-week treatment vs. baseline | Serum | Human | Down |
| Study M028 | Type2 | sertraline group 4-week treatment vs. baseline | Serum | Human | Down |
| Study M040 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M075 | Type1 | post stroke depressed group vs. post stroke non-depressed group | Plasma | Human | Up |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA3 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | DG region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA1 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | DG region of hippocampus | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA1 region of hippocampus | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA3 region of hippocampus | ICR mouse | Up |
| Study M1045 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M1045 | Type1 | anxiety and depression group vs. control group | Plasma | Human | Down |
| Study M1090 | Type3 | hyperbaric oxygen treatment group vs. control group | Plasma | BALb/c mouse | Up |
| Study M1111 | Type1 | CUMS group vs. control group | Plasma | C57BL/6 mouse | Down |
| Study M1111 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M1111 | Type2 | CUMS + rTMS group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M1142 | Type2 | MDD group, after intermittent theta burst stimulation vs. baseline | Plasma | Human | Down |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M207 | Type1 | depressed group vs. control group | Serum | Kunming mouse | Up |
| Study M464 | Type1 | drug-treatment MDD group vs. control group | Plasma | Human | Down |
| Study M464 | Type1 | drug-naive MDD group vs. control group | Plasma | Human | Down |
| Study M472 | Type3 | (2S,6S)-HNK group vs. control group | PC12 cell | Rat | Down |
| Study M472 | Type3 | (2R,6R)-HNK group vs. control group | PC12 cell | Rat | Down |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M566 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M569 | Type2 | LPS + HPF group vs. LPS group | Serum | ICR mouse | Down |
| Study M600 | Type1 | high-fat diet group vs. control group | Forebrain | C57BL/6J mouse | Down |
| Study M600 | Type2 | high-fat diet + fish oil group vs. high-fat diet group | Forebrain | C57BL/6J mouse | Up |
| Study M610 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M610 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M669 | Type1 | corticosterone group vs. control group | Liver | C57BL/6J mouse | Up |
| Study M712 | Type1 | depression group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M738 | Type1 | CMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Up |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Up |
| Study M846 | Type2 | postpartum depression model + 919 syrup group vs. postpartum depression model group | Hippocampus | BALB/c mouse | Down |
| Study M883 | Type1 | MDD group vs. control group | Blood | Human | Up |
| Study M907 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M981 | Type1 | Abeta oligomer group vs. control group | Serum | ICR mouse | Up |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running group vs. Abeta oligomer group | Serum | ICR mouse | Down |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running + acousto-optic stimulation group vs. Abeta oligomer group | Serum | ICR mouse | Down |